Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

28.04.22	Lilly: Tirzepatide In SURMOUNT-1 Trial Delivers Superior Weight Loss In Adults (RTTNews)
28.04.22	Eli Lilly Q1 Results Top Estimates; Boosts FY22 Revenue Outlook (RTTNews)
28.04.22	Eli Lilly And Co. Reveals Increase In Q1 Profit (RTTNews)
28.04.22	Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022 (PR Newswire)
28.04.22	Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 (PR Newswire)
28.04.22	Ausblick: Eli Lilly and verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) Bei Eli Lilly and stehen Quartalszahlen ins Haus. Was Experten erwarten.» mehr
26.04.22	Bachem-Aktie springt hoch: Bachem kooperiert mit Eli Lilly (AWP) Das Biochemie-Unternehmen Bachem geht eine strategische Partnerschaft mit Eli Lilly and Company ein.» mehr
20.04.22	Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care (PR Newswire)
19.04.22	Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement (PR Newswire)
19.04.22	Form 4 59478 (RSS)
14.04.22	Pharmaindustrie: Angebot von Corona-Impfstoffen übersteigt Nachfrage (AWP)
13.04.22	Erste Schätzungen: Eli Lilly and verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
11.04.22	Lilly's Lebrikizumab - Corticosteroids Show Improvements In Disease Severity For Atopic Dermatitis (RTTNews)
11.04.22	Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis (PR Newswire)
07.04.22	Form 4 59478 (RSS)
01.04.22	Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress (PR Newswire)
29.03.22	Form 4 59478 (RSS)
28.03.22	Innovent Biologics, Lilly Expand Partnership In Oncology (RTTNews)
28.03.22	Innovent and Lilly Expand Strategic Partnership in Oncology (PR Newswire)
26.03.22	Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies (PR Newswire)
26.03.22	Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies (PR Newswire)
24.03.22	Eli Lilly: FDA Issues CRL For BLA For Sintilimab; Unable To Approve Application In Its Current Form (RTTNews)
24.03.22	Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer (PR Newswire)
18.03.22	Statement of changes in beneficial ownership of securities (RSS)
17.03.22	Form 4 59478 (RSS)
16.03.22	Eli Lilly: EMPA-KIDNEY Trial Shows Efficacy For Jardiance At Early Stage; Trial To Stop (RTTNews)
16.03.22	Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease (PR Newswire)
14.03.22	Boeing : Arajet Orders 20 737 MAX Aircraft (RTTNews)
08.03.22	Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) (PR Newswire)
07.03.22	Form 4 59478 (RSS)
03.03.22	Lilly to Participate in Barclays Global Healthcare Conference (PR Newswire)
01.03.22	Eli Lilly Says Jardiance Provides Significant Benefit In Adults Following Acute Heart Failure (RTTNews)
01.03.22	Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial (PR Newswire)
28.02.22	Lilly to Participate in Cowen Health Care Conference (PR Newswire)
28.02.22	Biotech Stocks Facing FDA Decision In March 2022 (RTTNews)
25.02.22	FDA Approves Jardiance To Treat Adults With Heart Failure (RTTNews)
24.02.22	US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction (PR Newswire)
24.02.22	Form 4 59478 (RSS)
22.02.22	Lilly Launches Institute For Genetic Medicine; Invests $700 Mln (RTTNews)
22.02.22	Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site (PR Newswire)
18.02.22	Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study (PR Newswire)
16.02.22	Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence (PR Newswire)
11.02.22	FDA Issues Emergency Use Authorization For Eli Lilly's Covid-19 Treatment (RTTNews)
11.02.22	Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 (PR Newswire)
11.02.22	FDA Panel Votes Against Lilly's Lung Cancer Drug For China-only Trial (RTTNews)
11.02.22	Form 4 59478 (RSS)
11.02.22	Lilly Reaches Deal With U.S. To Supply Up To 600,000 Doses Of Bebtelovimab For COVID-19 Treatment (RTTNews)
10.02.22	Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (PR Newswire)
10.02.22	Form SC 13G 59478 (RSS)
03.02.22	Eli Lilly Q4 Results Top Estimates; Reaffirms FY22 Outlook (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.51	0.63 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	77.94	0.41 %	K V
Roche Hldg G	252.00	0.24 %	K V
Kuehne+Nagel Int	209.00	0.19 %	K V
UBS Group	27.58	-0.65 %	K V
ABB	49.02	-1.05 %	K V
Sika	225.70	-1.27 %	K V
Lonza Grp	521.60	-1.77 %	K V
Logitech Intl	69.92	-2.86 %	K V

mehr

15:58		Minuszeichen in Europa: STOXX 50 legt am Mittwochnachmittag den Rückwärtsgang ein
15:58		Handel in Europa: So bewegt sich der Euro STOXX 50 aktuell
15:58		Schwache Performance in Zürich: SLI nachmittags im Minus
15:58		Börse Zürich in Rot: So performt der SMI nachmittags
15:10		Novartis-Aktie etwas höher: EU-Zulassung für Kisqali - Funktion des Schweizer Länderpräsidenten gestrichen
13:28		Bayer-Analyse: DZ BANK verleiht Bayer-Aktie Kaufen in jüngster Analyse
12:26		Schwacher Wochentag in Europa: So performt der Euro STOXX 50 mittags
12:26		Börse Zürich in Rot: SLI gibt nach

15:58

Minuszeichen in Europa: STOXX 50 legt am Mittwochnachmittag den Rückwärtsgang ein

15:58

Handel in Europa: So bewegt sich der Euro STOXX 50 aktuell

15:58

Schwache Performance in Zürich: SLI nachmittags im Minus

15:58

Börse Zürich in Rot: So performt der SMI nachmittags

15:10

Novartis-Aktie etwas höher: EU-Zulassung für Kisqali - Funktion des Schweizer Länderpräsidenten gestrichen

13:28

Bayer-Analyse: DZ BANK verleiht Bayer-Aktie Kaufen in jüngster Analyse